Employing approximately 150000 people in134 offices in 62 countries the company consists of two main business units:Digital Media & Communications
Employing approximately 150,000 people in134 offices in 62 countries, the company consists of two main business units:Digital Media & Communications and Device Solutions. Recognized as one of thefastest growing global brands, Samsung Electronics is a leading producer ofdigital TVs, memory chips, mobile phones and TFT-LCDs. For more information,please visit Photos/Multimedia Gallery Available: http:// Electronics AmericaJason Redmond, 201-807-3136Information Technology Copyright Business Wire 2009. He never takes a night off, and is better than Cherepanov, and possibly better than Malkin and Ovechkin He was born May 25, 1990 in Moscow, Russia. He is 6′0″, 165 pounds, and a right-handed shot, which is not always good for a left winger, but it is great in this case.Filatov, ranked number two by the International Scouting Service, played in the WU18 league for Russia in 2006-2007, scoring four goals and five assists in seven games for nine points.This year, however, he played in the Rus. 2 league for the Central Army, scoring 24 goals and 23 assists for 47 points in 23 games. In the World Junior Championships, he scored four goals and five assists for nine points in seven games.Scouts have said that he is better than Alexander Ovechkin and Evgeni Malkin. Others have said he is close to their level, but not better. Either way, though, no one will disagree with the statement that he is one of the best players in the world not playing in the NHL, if not the best played outside of the NHL.Whoever chooses Filatov come June, if they can get him out of Russia, will be blessed with a superstar for the next 20-or-so years. He is going to be a star in this league when he comes over, and the NHL is already licking their chops to see another scorer join Ovie and the gang..
Highlights Emerging Technologies and Clinical Data on New and Existing ProductsWATERTOWN, Mass.–(Business Wire)–pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a leading drug delivery company,today announced that seven abstracts describing its ophthalmic drug deliveryproducts and technologies have been accepted by the Association for Research inVision and Ophthalmology (ARVO) for presentation at the upcoming 2009 AnnualMeeting to be held May 3-7 in Fort Lauderdale, Florida. The presentations will focus both on the development of pSivida`s nextgeneration bioerodible technologies for ophthalmic drug delivery and on clinicalresults from the company`s Iluvien program in diabetic macular edema (DME), aswell as ongoing work with the FDA approved device Retisert. pSivida is arecognized leader in ophthalmic drug delivery having developed the onlytreatments currently approved by the U.S. Food and Drug Administration (FDA) forsustained back-of-the-eye drug delivery: Vitrasert and Retisert, both of whichare licensed to Bausch & Lomb, and the Iluvien product currently in fullyenrolled Phase III clinical trials conducted by the Company`s licensing partnerAlimera Sciences. The NDA filing for Iluvien remains on schedule for early 2010.”We are extremely pleased to have multiple abstracts featuring our products andtechnologies accepted for presentation at the ARVO meeting. These presentationshighlight our advancements in bioerodible intraocular delivery systems as wellas data from recent clinical studies of the Iluvien Phase III product candidateand our FDA approved product Retisert,” stated Dr.
Paul Ashton, President andChief Executive Officer of pSivida. “Utilizing various proprietary technologies,including our BioSilicon technology, we are developing fully bioerodible devicesthat are designed to be easier to manufacture and administer. With what is now athird generation technology, there are multiple potential applications and manypartnership opportunities to facilitate future development.” pSivida has a worldwide collaborative research and license agreement with PfizerInc. for the Medidur technology under which Pfizer may develop additionalophthalmic products. Further details of the presentations and their conclusions will be availableafter presentation at the ARVO conference. About pSivida Corp.pSivida is a world leader in the development of miniaturized, injectable, drugdelivery systems for the eye. pSivida`s lead development product, Iluvien,delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema(DME).
